to Nature home page 
information
home
search
help




Malaria

Cover illustration
Coloured scanning electron micrograph of a Plasmodium falciparum protozoan with red blood cells
(Image courtesy of Eye of Science/SPL)

Vol. 415, No. 6872 (7 February 2002).
|PDF(106K)|

In any given year, nearly ten per cent of the global population will suffer from malaria — 500 million clinical cases — and more than 1 million will die as a result; a death from malaria every 30 seconds. In Africa, the disease kills one child in twenty before five years of age.

And things are getting worse, as malaria is undergoing a resurgence. The main contributing factors are the emergence of drug-resistant strains of the parasite, the appearance of mosquitoes (which transmit the parasite) that are resistant to insecticides, environmental changes and increased population.

After decades of relative lack of attention, growing international awareness and funding has led to new efforts towards controlling the disease. A wide-ranging coalition of interests is being marshalled to combat malaria, including: global healthcare planning, specifically the World Health Organization's 'Roll Back Malaria' campaign, which aims to halve the burden of disease by 2010; pharmaceutical industry support; research coordination, with the main funding agencies coming together in the Multilateral Initiative on Malaria; and philanthropy, most notably the Malaria Vaccine Initiative supported by the Bill and Melinda Gates Foundation.

While this points to an appropriate level of concern and urgency, the most critical challenge is to the researchers. Can they supply the knowledge and tools needed to combat this devastating disease? This Insight will go a long way to answering that question, describing latest research developments, likely future progress and the practical impact that the new knowledge will have.

Ursula Weiss Senior Editor

All of the articles in this Insight are free to registered users of Nature's web site. Registration is a simple process which should take only a few minutes to complete. You can sign up here.

Insight
introduction
Malaria in 2002
BRIAN GREENWOOD AND THEONEST MUTABINGWA

|Summary| Full text|PDF(125K)|
670
review articles
The pathogenic basis of malaria
LOUIS H. MILLER, DROR I. BARUCH, KEVIN MARSH & OGOBARA K. DOUMBO
|Summary|Full text|PDF(571K)|
673
The economic and social burden of malaria
JEFFREY SACHS AND PIA MALANEY
|Summary|Full text|PDF(215K)|
680
Medical need, scientific opportunity and the drive for antimalarial drugs
ROBERT G. RIDLEY
|Summary|Full text|PDF(389K)|
686
Progress and challenges for malaria vaccines
THOMAS L. RICHIE AND ALLAN SAUL
|Summary|Full text|PDF(334K)|
694
Plasmodium, human and Anopheles genomics and malaria
STEPHEN L. HOFFMAN, G. MANI SUBRAMANIAN, FRANK H. COLLINS & J. CRAIG VENTER
|Summary|Full text|PDF(204K)|
702
Satellite imagery in the study and forecast of malaria
DAVID J. ROGERS, SARAH E. RANDOLPH, ROBERT W. SNOW & SIMON I. HAY
|Summary|Full text|PDF(679K)|
710
corporate support
The Medicines for Malaria Venture
|Full text|PDF(176K)|
715
GlaxoSmithKline and malaria
|Full text|PDF(314K)|
716

 


Macmillan MagazinesNature © Macmillan Publishers Ltd 2000 Registered No. 785998 England.